MONDAY, June 24, 2024 -- For patients with resected stage III melanoma, adjuvant therapy with dabrafenib plus trametinib is associated with a...
Vous n'êtes pas connecté
TUESDAY, June 18, 2024 -- For children with relapsed or refractory juvenile myelomonocytic leukemia (JMML), trametinib is safe and effective, according to a study published online June 12 in Cancer Discovery. Noting that patients with relapsed or...
MONDAY, June 24, 2024 -- For patients with resected stage III melanoma, adjuvant therapy with dabrafenib plus trametinib is associated with a...
TUESDAY, June 25, 2024 -- For patients with prurigo nodularis (PN) and chronic pruritus of unknown origin (CPUO), abrocitinib, a Janus kinase 1...
COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved...
TUESDAY, June 25, 2024 -- Intermittent fasting may be a more effective intervention than drugs for people with early diabetes and either obesity or...
FRIDAY, June 21, 2024 -- First-line ibrutinib is associated with better outcomes than chemoimmunotherapy among patients with chronic lymphocytic...
FRIDAY, June 28, 2024 -- For patients with early-stage cervical cancer, disease-free and overall survival are lower for patients undergoing minimally...
WEDNESDAY, July 3, 2024 -- For patients with refractory gastroesophageal reflux disease (GERD), those receiving antireflux mucosectomy (ARMS) have a...
THURSDAY, June 20, 2024 -- Black patients are more likely to experience adverse cardiovascular outcomes after systemic androgen deprivation therapy...
THURSDAY, June 20, 2024 -- For patients with specific subtypes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), treatment with...
FRIDAY, June 28, 2024 -- Precision-guided treatment improves outcomes for children with high-risk cancer, according to a study published online June...